<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04883073</url>
  </required_header>
  <id_info>
    <org_study_id>ELEA</org_study_id>
    <nct_id>NCT04883073</nct_id>
  </id_info>
  <brief_title>Impact on Quality of Life of &quot;Endo-App&quot; (ELEA)</brief_title>
  <acronym>ELEA</acronym>
  <official_title>Impact on Quality of Life by Additional Use of the Digital Health Application &quot;Endo-App&quot; to Standard Therapy: Multicenter, Prospective, Randomised Trial (ELEA)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Muenster</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital Muenster</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      multicenter randomized controlled trial enrolment of endometriosis patients from certified&#xD;
      endometriosis centers randomization to control group (no Endo App use) vs intervention group&#xD;
      (Endo App use) 90 use / no use of Endo App evaluation of quality of life at onset, at 30, 60&#xD;
      and 90 days using endometriosis health profile (EHP) 30 summary index statistical analysis of&#xD;
      summary index at the end minus summary index at onset between control and intervention group&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      multicenter randomized controlled trial enrolment of endometriosis patients from certified&#xD;
      endometriosis centers 472 patients in total, 236 patients per group randomization to control&#xD;
      group (no Endo App use) vs intervention group (Endo App use) 90 use / no use of Endo App Endo&#xD;
      App is a german language certified health application which can be used to monitor the&#xD;
      disease and gives support by providing complementary interventions to standard therapy, it is&#xD;
      commercially available evaluation of quality of life at onset, at 30, 60 and 90 days using&#xD;
      endometriosis health profile (EHP) 30 summary index primary endpoint: change in EHP 30&#xD;
      summary index secondary endpoints: change in EHP domains pain, control and helplessness,&#xD;
      emotional wellbeing, social support, self perception, work, sexual intercourse, treatment&#xD;
      exploratory per protocol analysis statistical analysis of summary index at the end minus&#xD;
      summary index at onset between control and intervention group&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 2022</start_date>
  <completion_date type="Anticipated">May 2023</completion_date>
  <primary_completion_date type="Anticipated">April 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>multicenter randomized controlled trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>EHP 30 Summary Index</measure>
    <time_frame>90 days</time_frame>
    <description>Change in Endometriosis Health Profile 30 summary index (minimum value: 0 points, maximum value: 100 points, higher scores mean a worse outcome)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>EHP domains</measure>
    <time_frame>90 days</time_frame>
    <description>Change in EHP 30 domains pain, control and helplessness, emotional wellbeing, social support, self perception, work, sexual intercourse, treatment (minimum value: 0 points, maximum value: 100 points. higher scores mean a worse outcome)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">472</enrollment>
  <condition>Endometriosis</condition>
  <condition>Endometriosis-related Pain</condition>
  <condition>Quality of Life</condition>
  <arm_group>
    <arm_group_label>Endo App use</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>use of Endo App during trial</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>no use of Endo App during trial</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Use of Endo App</intervention_name>
    <description>Use of Endo App</description>
    <arm_group_label>Endo App use</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  endometriosis histologically proven&#xD;
&#xD;
          -  no operation or medical treatment currently performed or planned&#xD;
&#xD;
          -  capable of using a smartphone&#xD;
&#xD;
          -  willingness to use a smartphone and the Endo App&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  absence of inclusion criteria&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Sebastian D Schäfer</last_name>
    <phone>02518344107</phone>
    <email>sd.schaefer@ukmuenster.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>University Hospital Münster Germany</name>
      <address>
        <city>Münster</city>
        <state>NRW</state>
        <zip>48149</zip>
        <country>Germany</country>
      </address>
    </facility>
    <contact>
      <last_name>Sebastian D Schäfer, Dr</last_name>
      <phone>00492518344107</phone>
      <email>sd.schaefer@ukmuenster.de</email>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>May 6, 2021</study_first_submitted>
  <study_first_submitted_qc>May 6, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 12, 2021</study_first_posted>
  <last_update_submitted>September 27, 2021</last_update_submitted>
  <last_update_submitted_qc>September 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital Muenster</investigator_affiliation>
    <investigator_full_name>Dr. med. Sebastian Daniel Schäfer</investigator_full_name>
    <investigator_title>Head of Department of Gynecology</investigator_title>
  </responsible_party>
  <keyword>endometriosis</keyword>
  <keyword>EHP 30 summary index</keyword>
  <keyword>quality of life</keyword>
  <keyword>Endo-App</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Endometriosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

